The once-daily HIV treatment regimen offers a new mechanism of action in the HIV treatment market. More: Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso Source: fierce
read morePfizer’s chief strategy and innovation officer Andrew Baum is stepping down merely two years into the role, according to reports. More: Pfizer's strategy head Andrew Baum to step down following brief tenure: reports Source: fierce
read moreFierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo vie to become the go-to oral weight-loss solution
read moreIn a phase 3 trial in the rare kidney disease IgAN, AstraZeneca said its Ultomiris delivered a clinically meaningful and statistically significant reduction in protein from the urine after 34 weeks. More: AstraZeneca eyes 5th Ultomiris indication after kidney disease
read moreAfter prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect Welireg surprisingly failed to ignite hope as a first-line treatment. More: In a Merck Litespark shocker, Welireg triplet misses the mark in
read more© 1994 - 2026 B.M. Pharmaceuticals